MRM
MEDIROM Healthcare Technologies Inc. (MRM) 10Y Growth Potential Analysis (2026)
Overall Score
Growth
Revenue base is modest relative to enterprise value, with EV/Sales at 0.81x.
Operating performance remains negative, with EBIT margin at -19.8% and EBITDA margin at -12.9%.
Cash conversion is weak, with operating cash flow margin at -9.1% and free cash flow margin at -16.1%.
Profitability
Return metrics remain deeply negative, including ROE at -68.4% and ROIC at -19.3%.
Gross margin is only 25.3%, while operating margin is -19.8%.
Interest coverage is negative at -8.7x, reflecting ongoing earnings pressure.
Financial Health
Liquidity is acceptable with a current ratio of 1.75x and quick ratio of 1.75x.
Leverage remains elevated, with debt-to-equity at 1.75x and debt-to-assets at 56.1%.
Cash balance is thin relative to obligations, with cash per share at 2.55 and a cash ratio of 0.01x.
Valuation
The stock screens cheap on sales at 0.20x P/S and 0.85x P/B.
However, negative earnings and cash flow make P/E and cash flow multiples less meaningful.
Enterprise value remains high relative to cash generation, with EV/FCF at -8.5x and EV/OCF at -8.9x.
Momentum
No recent news was provided to indicate a positive catalyst.
The framework currently lacks evidence of improving operating momentum.
Absent fresh catalysts, the setup remains weak for a 10-year growth case.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MEDIROM Healthcare Technologies Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

